:format(webp)/cdn.mskdoctors.com/storage/2026/7/8ilKw2XCH5pB5TWOt6kewJNVnwz4zE0V.jpg)
What the ChondroFiller evidence actually showsChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/rgOU5joVFIvQSkaY3S921m8v6ZjDLgSd.jpg)
Who qualifies for a ChondroFiller injectionChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.ChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/UY0InSBaoOinSJHR9T3qmZrV7DMIQOXA.jpg)
ChondroFiller vs PRP for focal cartilage defectsFocal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying…Focal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying problem.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/2WlwnJj0faCPyw0ya8IAE2HzUDpZMpBK.jpg)
Who qualifies for ChondroFiller injectionChondroFiller targets Grade III and IV cartilage damage—focal defects or distributed osteoarthritis—using a collagen scaffold to support biological repair across both presentations, provided joint mechanical stability remains intact.ChondroFiller targets Grade III and IV cartilage damage—focal defects or distributed osteoarthritis—using a collagen scaffold to support biological repair across both presentations, provided joint mechanical stability remains intact.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/yIAGZGajyWr3EcFixjxB4VUoZIzQlkDg.jpg)
ChondroFiller injection vs knee replacementChondroFiller is a collagen scaffold injection that recruits the patient's own repair cells to treat focal cartilage defects. Knee replacement suits end-stage, widespread wear; the choice between them depends on imaging findings, not age.ChondroFiller is a collagen scaffold injection that recruits the patient's own repair cells to treat focal cartilage defects. Knee replacement suits end-stage, widespread wear; the choice between them depends on imaging findings, not age.
